In the role, Fisher serves on the company’s executive leadership team, reporting to President and CEO Massimo Calafiore. He succeeds Kimberley Etling, who departed Orthofix in July through a mutual separation agreement.
“Orthofix has a uniquely differentiated orthopedics portfolio with a history of clinical innovation that goes back to its early beginnings in 1980,” said Fisher. “I have long been aware of the great products and work done by the Orthofix orthopedics team, and I am honored to have the opportunity to lead this area of the organization. I look forward to working with the team to help drive growth and accelerate this important area of the business.”
Fisher joins from Stryker, where he held the position of VP and GM of the orthopedic giant’s Foot and Ankle business unit. He previously served as president of Wright Medical’s Lower Extremity and Biologics unit. At Wright, Fisher moved through multiple roles of increasing responsibility after joining in 2002, including VP of U.S. sales. Stryker acquired Wright Medical in 2020.
“Patrick has led global teams in the successful development and execution of innovative strategies focused on driving commercial optimization across sales, marketing, R&D, clinical research and medical education,” said Calafiore. “We are excited to welcome him to our team, and I am confident his leadership, experience and broad familiarity with the Orthopedics market will help us further grow this franchise and expand our market presence.”
More leadership changes for Orthofix
Fisher’s appointment marks yet another change at the top for Orthofix, which has dealt with plenty of movement since terminating three executives with cause in September. Orthofix cut ties with CEO Keith Valentine, CFO John Bostjancic and chief legal officer Patrick Keran following an investigation.
Orthofix named Calafiore CEO in November 2023. In January 2024, Julie Andrews took over as CFO, followed by the appointment of Andres Cedron as chief legal officer in April.
The company also appointed Aviva McPherron as president of its global operations and quality. Not long after, Julie Dewey became the company’s new chief investor relations and communications officer. Max Reinhardt also began his tenure as president of the company’s global spine business at that time.
